|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Novel drugs in the areas of infectious disease, inflammation and oncology. |
|
| Management |
| Michael T. Flavin, Ph.D., Chief Executive Officer and Chairman; John L. Flavin, M.B.A., President, Chief Financial Officer and Director; Suseelan Pookote, Ph.D., Executive Vice President of Corporate Development; Ze-Qi Xu Ph.D., Executive Vice President and Chief Scientific Officer; David A. Eiznhamer, Ph.D., Executive Vice President of Clinical Development |
| |
|
|
|
|
|
|
|
| Keywords |
| respiratory tract infections, human immunodeficiency virus, HIV, acute respiratory distress syndrome, cancer., HIVAIDS |
|
|
|
| Description |
|
Advanced Life Sciences is focused on the discovery, development and commercialization of novel drugs in the areas of infectious disease, inflammation and oncology. |
|
| Products / Services |
Using their internal discovery capabilities and a network of pharmaceutical and academic partners, they have assembled a pipeline of clinical and preclinical product candidates for the treatment of respiratory tract infections, human immunodeficiency virus, acute respiratory distress syndrome and cancer.
The Company has three product candidates that are either in clinical development or approved to begin clinical development, as well as six additional candidates in preclinical development.
Advanced Life Sciences is focusing its resources on the development and commercialization of cethromycin for use in respiratory tract infections such as community acquired pneumonia, bronchitis and sinusitis.
|
|
| Technology / Differentiation |
| Advanced Life Sciences has assembled a promising pipeline of clinical and preclinical candidates using its internal discovery platform of natural product optimization through medicinal chemistry and structural biology, coupled with in-licensing promising new products. |
|
|
| Strategy |
The Company recently announced the completion of its two pivotal phase III clinical trials in community acquired pneumonia in which cethromycin achieved its primary endpoint of demonstrating non-inferiority compared to the current standard of care. Advanced Life Sciences plans to partner with other organizations to advance its earlier stage programs.
|
|
| Status |
| They currently have four product candidates that are approved for or currently in clinical development, and seven additional product candidates that are in preclinical development. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
